Literature DB >> 33217178

Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post-Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction: An Advancing Liver Therapeutic Approaches Group Study.

Jin Ge1, Jennifer C Lai1, Justin Richard Boike2, Margarita German3, Nathaniel Jest4, Giuseppe Morelli4, Erin Spengler3, Adnan Said3, Alexander Lee3, Alexander Hristov3, Archita P Desai5, Shilpa Junna6, Bhupesh Pokhrel6, Thomas Couri7, Sonali Paul7, Catherine Frenette8, Nathaniel Christian-Miller9, Marcela Laurito10, Elizabeth C Verna10, Usman Rahim11, Aparna Goel12, Arighno Das2, Stewart Pine2, Dyanna Gregory2, Lisa B VanWagner2, Kanti Pallav Kolli13.   

Abstract

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective intervention for portal hypertensive complications, but its effect on renal function is not well characterized. Here we describe renal function and characteristics associated with renal dysfunction at 30 days post-TIPS. Adults with cirrhosis who underwent TIPS at 9 hospitals in the United States from 2010 to 2015 were included. We defined "post-TIPS renal dysfunction" as a change in estimated glomerular filtration rate (ΔeGFR) ≤-15 and eGFR ≤ 60 mL/min/1.73 m2 or new renal replacement therapy (RRT) at day 30. We identified the characteristics associated with post-TIPS renal dysfunction by logistic regression and evaluated survival using adjusted competing risk regressions. Of the 673 patients, the median age was 57 years, 38% of the patients were female, 26% had diabetes mellitus, and the median MELD-Na was 17. After 30 days post-TIPS, 66 (10%) had renal dysfunction, of which 23 (35%) required new RRT. Patients with post-TIPS renal dysfunction, compared with those with stable renal function, were more likely to have nonalcoholic fatty liver disease (NAFLD; 33% versus 17%; P = 0.01) and comorbid diabetes mellitus (42% versus 24%; P = 0.001). Multivariate logistic regressions showed NAFLD (odds ratio [OR], 2.04; 95% confidence interval [CI], 1.00-4.17; P = 0.05), serum sodium (Na; OR, 1.06 per mEq/L; 95% CI, 1.01-1.12; P = 0.03), and diabetes mellitus (OR, 2.04; 95% CI, 1.16-3.61; P = 0.01) were associated with post-TIPS renal dysfunction. Competing risk regressions showed that those with post-TIPS renal dysfunction were at a higher subhazard of death (subhazard ratio, 1.74; 95% CI, 1.18-2.56; P = 0.01). In this large, multicenter cohort, we found NAFLD, diabetes mellitus, and baseline Na associated with post-TIPS renal dysfunction. This study suggests that patients with NAFLD and diabetes mellitus undergoing TIPS evaluation may require additional attention to cardiac and renal comorbidities before proceeding with the procedure.
Copyright © 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2021        PMID: 33217178      PMCID: PMC8053375          DOI: 10.1002/lt.25949

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  31 in total

1.  The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt.

Authors:  F Wong; K Sniderman; P Liu; L Blendis
Journal:  Gastroenterology       Date:  1997-03       Impact factor: 22.682

Review 2.  NAFLD: a multisystem disease.

Authors:  Christopher D Byrne; Giovanni Targher
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

3.  Chapter 1: Definition and classification of CKD.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2013-01

4.  Sex specificity of kidney markers to assess prognosis in cirrhotic patients with TIPS.

Authors:  Maria Torner; Adjmal Mangal; Hubert Scharnagl; Christian Jansen; Michael Praktiknjo; Alexander Queck; Wenyi Gu; Robert Schierwagen; Jennifer Lehmann; Frank E Uschner; Christiana Graf; Christian P Strassburg; Javier Fernandez; Tatjana Stojakovic; Rainer Woitas; Jonel Trebicka
Journal:  Liver Int       Date:  2019-09-10       Impact factor: 5.828

5.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

Authors:  Andrew S Levey; Kai-Uwe Eckardt; Yusuke Tsukamoto; Adeera Levin; Josef Coresh; Jerome Rossert; Dick De Zeeuw; Thomas H Hostetter; Norbert Lameire; Garabed Eknoyan
Journal:  Kidney Int       Date:  2005-06       Impact factor: 10.612

6.  Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites.

Authors:  A L Gerbes; V Gülberg; T Waggershauser; J Holl; M Reiser
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

Review 7.  TIPS: 25 years later.

Authors:  Martin Rössle
Journal:  J Hepatol       Date:  2013-06-25       Impact factor: 25.083

8.  A Model for Glomerular Filtration Rate Assessment in Liver Disease (GRAIL) in the Presence of Renal Dysfunction.

Authors:  Sumeet K Asrani; Linda W Jennings; James F Trotter; Josh Levitsky; Mitra K Nadim; W R Kim; Stevan A Gonzalez; Bernard Fischbach; Ranjeeta Bahirwani; Michael Emmett; Goran Klintmalm
Journal:  Hepatology       Date:  2019-02-20       Impact factor: 17.425

9.  Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites.

Authors:  F Wong; K Sniderman; P Liu; Y Allidina; M Sherman; L Blendis
Journal:  Ann Intern Med       Date:  1995-06-01       Impact factor: 25.391

Review 10.  Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Giovanni Musso; Roberto Gambino; James H Tabibian; Mattias Ekstedt; Stergios Kechagias; Masahide Hamaguchi; Rolf Hultcrantz; Hannes Hagström; Seung Kew Yoon; Phunchai Charatcharoenwitthaya; Jacob George; Francisco Barrera; Svanhildur Hafliðadóttir; Einar Stefan Björnsson; Matthew J Armstrong; Laurence J Hopkins; Xin Gao; Sven Francque; An Verrijken; Yusuf Yilmaz; Keith D Lindor; Michael Charlton; Robin Haring; Markus M Lerch; Rainer Rettig; Henry Völzke; Seungho Ryu; Guolin Li; Linda L Wong; Mariana Machado; Helena Cortez-Pinto; Kohichiroh Yasui; Maurizio Cassader
Journal:  PLoS Med       Date:  2014-07-22       Impact factor: 11.069

View more
  3 in total

1.  Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH).

Authors:  Giada Sebastiani; Keyur Patel; Vlad Ratziu; Jordan J Feld; Brent A Neuschwander-Tetri; Massimo Pinzani; Salvatore Petta; Annalisa Berzigotti; Peter Metrakos; Naglaa Shoukry; Elizabeth M Brunt; An Tang; Jeremy F Cobbold; Jean-Marie Ekoe; Karen Seto; Peter Ghali; Stéphanie Chevalier; Quentin M Anstee; Heather Watson; Harpreet Bajaj; James Stone; Mark G Swain; Alnoor Ramji
Journal:  Can Liver J       Date:  2022-02-04

Review 2.  The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls.

Authors:  Hae Lim Lee; Sung Won Lee
Journal:  Clin Mol Hepatol       Date:  2021-09-27

3.  Outcomes After TIPS for Ascites and Variceal Bleeding in a Contemporary Era-An ALTA Group Study.

Authors:  Justin Richard Boike; Nikhilesh Ray Mazumder; Kanti Pallav Kolli; Jin Ge; Margarita German; Nathaniel Jest; Giuseppe Morelli; Erin Spengler; Adnan Said; Jennifer C Lai; Archita P Desai; Thomas Couri; Sonali Paul; Catherine Frenette; Elizabeth C Verna; Usman Rahim; Aparna Goel; Dyanna Gregory; Bartley Thornburg; Lisa B VanWagner
Journal:  Am J Gastroenterol       Date:  2021-10-01       Impact factor: 12.045

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.